Page 47 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
P. 47

SPARTAN Primary Endpoint: Metastasis-Free Survival



          • 72% reduction in the risk of metastases or death








                                                                                                            APA, 40.5 mo
                                                                                                            (median)




                                                         PBO, 16.2 mo                                  24-month additional MFS
                                                         (median)                                            benefit with APA














        APA = apalutamide; MFS = metastasis-free survival; PBO = placebo   MFS defined as the time from randomization to the first detection of distant metastasis
                                                                         on imaging (by blinded independent central review) or death from any cause, whichever
        Smith MR, et al. N Engl J Med. 2018;378:1408-18.
                                                                         occurred first.                                                      47
   42   43   44   45   46   47   48   49   50   51   52